An Illegal Deal Moves Up to $2B in Disease Research Money to the Pentagon

I am writing to urge you to exercise immediate oversight of a secret interagency agreement between the Department of Defense and the National Institutes of Health that enables the diversion of billions in civilian infectious disease research funds to the Pentagon. The agreement was signed August 4 by the Pentagon’s biodefense chief, Robert Kadlec, and August 5 by NIH Director Jay Bhattacharya, without proactively notifying Congress. NIH disclosed its existence only after House Appropriations Committee Democrats pressed for information. While the text sets no fixed dollar cap, reporting and internal documents confirm the framework—dubbed "Operation Prevailing Edge"—could draw up to $2 billion from the National Institute of Allergy and Infectious Diseases (NIAID), nearly a third of its annual budget. Discussions narrowed to initial project transfers of up to $700 million, with annual transfers expanding over the contract's 10-year term through 2036. The text explicitly allows NIH funds to pay for DoD program management personnel and internal overhead. The timing is not incidental. The Pentagon is six months into an open-ended war with Iran and waiting on Congress to approve a $95 billion supplemental request. Redirecting appropriated NIH research funds to defense priorities is not genuine collaboration—it is using a civilian health agency’s budget to paper over a defense gap created by a war Congress did not fully fund and voted twice to limit. While agency leadership claims no money has moved yet and frames this as routine cooperation, the mechanism itself is the threat. An open-ended 10-year contract that creates a pipeline to shift research authority and taxpayer funds to military entities without a congressional vote is a direct evasion of Article I oversight. This framework raises severe statutory violations: - VIOLATION OF THE PURPOSE STATUTE (31 U.S.C. § 1301(a)): Appropriated funds must be applied solely to the specific objects for which Congress enacted them. Infectious disease research dollars cannot serve as a discretionary reserve for defense shortfalls. - UNLAWFUL AUGMENTATION OF DEFENSE APPROPRIATIONS: Congress provides dedicated chemical and biological defense funding to DoD. Tapping civilian agencies without explicit statutory transfer authority unlawfully augments the defense budget. - DISTORTION OF THE ECONOMY ACT (31 U.S.C. § 1535): Interagency agreements exist to procure specific, cost-effective goods or services, not to operate as an open-ended pipeline transferring hundreds of millions of dollars without explicit statutory authorization. I urge you to take immediate action: 1. Demand the immediate termination of this interagency agreement pending full congressional committee review. 2. Require the administration to disclose all unredacted schedules, project lists, and administrative fee structures associated with "Operation Prevailing Edge". 3. Request a formal legal decision from the Government Accountability Office (GAO) on whether this arrangement violates federal appropriations law and the Antideficiency Act. Congress appropriated these funds to fight deadly civilian pathogens, not to backfill a defense budget. Enforce your power of the purse and stop this transfer immediately.